DLA Piper is acknowledged as one of the world’s leading legal services providers, representing companies and investors in the biotechnology, pharmaceutical and medical device fields. Our life sciences team operates across multiple practice groups and offices in an open, flexible manner. The team brings industry know-how, international deal experience and a thorough knowledge of local law to benefit life sciences clients in the leading global markets for research, commercialization and finance. As a truly global legal services provider, we serve all our clients’ needs from early stage venture-backed companies to the largest global providers of life-saving drugs, diagnostics and medical devices.
Life sciences clients look to their lawyers to understand their business and technology, anticipate legal problems and understand current regulations and laws as they relate specifically to their segment of the industry. Lawyers must be able to provide timely, proactive, creative and practical advice and solutions in a cost-efficient manner. DLA Piper’s experience and commitment to the life sciences industry make us a value-adding strategic partner for our clients.
Our firmwide life sciences practice is part of our Global Life Sciences sector, which takes a business unit approach to providing legal services to our clients. We are home to more than 200 lawyers and patent agents working together in the key life sciences markets around the world . In addition to our broad US coverage, we have a far-reaching presence in Europe and Asia, and strong ties to the principal business, finance and technology hubs worldwide, allowing us to effectively counsel and represent life companies and financiers in the global marketplace.
Our services including the following areas:
- IP, product development and licensing: patents, trademarks and other intellectual property protection, strategic alliances and corporate partnering, and product sales and marketing
- Corporate and finance - public and private corporate finance, corporate governance, M&A, and domestic and international taxation
- Government affairs and competition/antitrust - trade regulation issues, government contracts, international trade and unfair competition
- Infrastructure services - real estate and facility development, human resources and IT development
- Litigation - product liability, commercial disputes, consumer class actions and intellectual property disputes
- Regulatory and clinical trials - FDA, EMEA, and other regulatory agency strategies, processes and public policy issues